Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF fusion |
Therapy | Cobimetinib |
Indication/Tumor Type | Erdheim-Chester disease |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF fusion | Erdheim-Chester disease | predicted - sensitive | Cobimetinib | Case Reports/Case Series | Actionable | In a retrospective analysis, Cotellic (cobimetinib) treatment resulted in a partial response with a tumor reduction of 67% in a patient with Erdheim-Chester disease harboring a BRAF fusion, with the patient remaining on treatment for at least 22 months (PMID: 38922339; NCT01775072). | 38922339 |
PubMed Id | Reference Title | Details |
---|---|---|
(38922339) | Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets. | Full reference... |